Aclaris Therapeutics, Inc. Announces Positive Results from Phase 2 Clinical Trial of A-101 for the Removal of Seborrheic Keratosis
Jun 30 14
Aclaris Therapeutics, Inc. announced positive results from a Phase 2 clinical trial of the company's drug, A-101. In the trial, A-101 demonstrated clinically and statistically significant improvements in clearing seborrheic keratoses to have SK treated either because the lesions have become irritated or are cosmetically concerning. The double-blind, placebo-controlled Phase 2 clinical trial was designed to evaluate the safety, tolerability, and efficacy of A-101 in removing SK lesions. The trial used a within-subject design to compare three concentrations of A-101 and vehicle (placebo) in 35 patients with SK lesions. A-101 achieved statistical significance in clearing SK lesions on the back in a dose-related fashion. A-101 was well tolerated at all concentrations.
Aclaris Therapeutics, Inc. Announces Management Changes
Oct 24 12
Aclaris Therapeutics, Inc. announced that Dr. Neal Walker, a board-certified dermatologist and experienced entrepreneur, will lead the company as Chief Executive Officer, President and Director. Dr. Walker has co-founded a number of life-science companies and brings more than eighteen years of pharmaceutical industry experience in research and development, regulatory affairs and business development to the company. Most recently, Dr. Walker served as Founder, CEO and Director of Vicept Therapeutics. Dr. Walker also co-founded Octagon Research Solutions, Inc. and served as its Director until August 2012. Stephen Tullman, the former Executive Chairman of Vicept, will serve as Chairman of the Board of Directors of the company. He currently serves as President and CEO of Ceptaris Therapeutics, Inc. In addition, he is Managing Partner of NeXeption. Albert Cha, M.D., Ph.D. and Ketan Patel, M.D. will join Mr. Tullman and Dr. Walker on the Board of Directors of the company. Dr. Cha is a managing partner at Vivo Ventures, where he invests in private and public biopharmaceutical and medical device companies. Dr. Patel is a principal with Fidelity Biosciences, where he focuses on investing in private life sciences companies globally.